Source comparison
BPC-157 Research Immune Considerations: Protocol Comparison
Dose Range Tested Single mid-range dose (e.g., 100 mcg/kg) Multi-dose arms: 10, 100, 500 mcg/kg minimum Local anti-inflammatory effects plateau at lower doses than systemic immune modulation. Single-dose studies miss threshold behaviour Multi-dose stratificati
This comparison does not assign a generated winner or score.
- Dose Range Tested
- Single mid-range dose (e.g., 100 mcg/kg)
- Multi-dose arms: 10, 100, 500 mcg/kg minimum
- Local anti-inflammatory effects plateau at lower doses than systemic immune modulation. Single-dose studies miss threshold behaviour
- Multi-dose stratification required to distinguish tissue-level from systemic immune effects
- Timing of Measurements
- Single endpoint at 24 or 48 hours
- Dual timepoints: 0–24h (acute inflammation) and 72–120h (regulatory response)
- Cytokine profile shifts from pro-inflammatory to regulatory over time. Single timepoints capture incomplete data
- Early and late measurements capture phenotype shift that defines BPC-157's mechanism
- Biomarkers Measured
- IL-6, TNF-α, CRP (acute-phase proteins)
- IL-6, TNF-α, IL-10, TGF-β, Treg counts, M1/M2 macrophage ratios
- Standard inflammatory markers show reduction but don't reveal regulatory immune activation that distinguishes peptide mechanism
- Regulatory markers (IL-10, TGF-β, Tregs) distinguish modulation from suppression
- Route of Administration
- Intraperitoneal (IP) injection only
- IP vs subcutaneous comparison arms
- IP produces higher peak plasma levels but subcutaneous better models clinical translation. Route affects both bioavailability and immune cell exposure kinetics
- Subcutaneous administration required if translating to human protocols
- Control for Confounders
- Vehicle control only
- Vehicle + NSAID comparison + peptide-only arm
- Without NSAID comparison, studies can't distinguish peptide-specific pathways from overlapping prostaglandin effects
- NSAID comparison arm clarifies whether effects are COX-independent